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Abstract
Background: Patient-reported outcomes (PROs) are the only instruments available
to assess the efﬁcacy of an intervention in patients with allergic rhinoconjunctivitis.
As allergic rhinoconjunctivitis is a systemic disease, it is now recommended to use
not only PROs focusing at classical symptoms, but also health-related quality of life
(HRQL) instruments in immunotherapy trials.
Methods: A previously published immunotherapy trial in children and adolescents
(6–18 yr) with hay fever provided us with data to assess the relevance of two of
these additional outcome measures, the disease-speciﬁc rhinoconjunctivitis quality of
life questionnaire (RQLQ) and the generic COOP/WONCA-charts (CWC). A PRO
was considered relevant if it was responsive to pollen exposure and at least had a
moderate correlation with the classical symptoms of allergic rhinoconjunctivitis.
Furthermore, we evaluated a post-season PRO, that is, a global assessment of symp-
toms (GAS). This assessment is used in clinical trials as a tool for selecting partici-
pants with sufﬁcient symptoms and in daily practice to evaluate the patient’s
complaints during the preceding season. We assessed the correlation of this retro-
spective score with the actual symptoms during the previous pollen season.
Results: Data from 36 children and 63 adolescents were analysed. On the basis of the
total scores of the paediatric and adolescent version of the RQLQ, both questionnaires
were considered relevant as they were responsive to exposure and showed a moderate to
strong correlation with the rhinoconjunctivitis symptoms. However, in both children
and adolescents, 40% of the RQLQ items were not relevant according to our deﬁnition.
The CWC as a whole and the separate charts appear less relevant because of the weak
correlations with the daily symptom score from the diary. The correlation between our
post-season GAS and the in season daily symptom score was weak.
Conclusion: The paediatric and adolescent RQLQ are relevant, but could be short-
ened as they contain a substantial number of irrelevant items. The CWC are not rel-
evant in the monitoring of children and adolescents with allergic rhinoconjunctivitis
caused by grass pollen. The retrospective GAS does not sufﬁciently reﬂect the actual
symptoms during the preceding season.
Abbreviations
D, changes of scores between high and low pollen period; AdolRQLQ, adolescent rhinoconjunctivitis quality of life questionnaire; CWC,
COOP/WONCA-charts; DC, diary card; GA2LEN, global allergy and asthma european network; GAS, global assessment of symptoms; HRQL,
Health-related quality of life; MID, minimal important difference; PRO, patient-reported outcome; PRQLQ, paediatric rhinoconjunctivitis
quality of life questionnaire; RCT, randomized controlled trial; RQLQ, rhinoconjunctivitis quality of life questionnaire; WAO, World Allergy
Organization.
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Allergy is a systemic disease. Patients with allergic rhinocon-
junctivitis do not only suffer from nose and eye symptoms,
but also suffer from general complaints such as fatigue, sleep-
ing problems and difﬁculty concentrating (1). As a result,
allergic rhinoconjunctivitis interferes with many aspects of
daily life (2). Focusing on symptoms alone might therefore
not fully reﬂect the impact of this allergic disease. To esti-
mate the burden of a disease as perceived by the patient,
health-related quality of life (HRQL) can be assessed. Nowa-
days, the demonstration of the effects on quality of life in
immunotherapy trials is recommended by the World Allergy
Organization (WAO) and the Global Allergy and Asthma
European Network (GA2LEN) (3, 4). So far, quality of life
outcome measures were included in only a few immunother-
apy trials with inhalant allergens in children (5–7). Although
well accepted, it is not known how relevant the inclusion of
these HRQL instruments is. A previously published immuno-
therapy trial in children and adolescents (6–18 yr) with hay
fever provided us with data to investigate the relevance of a
disease-speciﬁc and a general HRQL measure. For the assess-
ment of the disease-speciﬁc quality of life, the most widely
used and validated paediatric and adolescent version of the
rhinoconjunctivitis quality of life questionnaire (RQLQ) was
used (8, 9). Several generic quality of life questionnaires for
children have been developed. However, most lists are long
(up to 153 items), the applicability in different cultures is
often unknown and none of the lists are widely used (10). We
explored the use of the COOP/WONCA-charts (CWC) (11–
13) in our population, in spite of the fact that this instrument
has been validated for adults only and not for children or
adolescents. The CWC measure the functional health status
and have three major advantages. First, it is a short question-
naire consisting of six questions. Secondly, the answers are
illustrated with a simple drawing, which might facilitate the
use in our age group. Thirdly, the CWC appear to have low
susceptibility to cultural differences (13).
In addition to these two in season patient-reported out-
comes (PROs), we also asked the participants to complete a
global assessment of symptoms after the grass pollen season
to evaluate their complaints in the preceding months. This
assessment is often used as a tool for selecting participants
with sufﬁcient symptoms in clinical trials. In daily clinical
practice, physicians often rely on such retrospective state-
ments from their patients to evaluate symptoms and treat-
ment effects during the previous season.
In this study, we ﬁrst aimed to assess the relevance of the
HRQL PROs by studying the inﬂuence of pollen exposure
and the relationship with the classical features of allergic rhi-
noconjunctivitis. A PRO was considered relevant if it was
responsive to pollen exposure and at least had a moderate
correlation with the daily symptom score. Secondly, we were
also interested in the most important impairments as per-
ceived by the participants in a low and a high pollen period
as well as possible differences between periods. Finally, we
investigated how well the retrospective global assessment of
symptoms represented the actual complaints during the sea-
son. We considered the retrospective score to be an adequate
reﬂection of these complaints if the correlation with the daily
symptom score was strong.
Methods
Participants
A detailed description of the randomized double-blind pla-
cebo-controlled trial has been reported elsewhere (5). A total
of 204 children and adolescents aged 6–18 yr (mean age [SD]
12.9 [2.8] yr; 114 boys and 90 girls) with hay fever were
enrolled from general family practices in the Netherlands. All
participants had IgE antibodies to grass pollen ‡0.7 kU/l
(Phadia) and a history of rhinoconjunctivitis. The latter was
assessed by a retrospective symptom score: participants
scored ﬁve symptoms (sneezing, itching nose, watery running
nose, nasal blockage and itching eyes) during the previous
grass pollen season (May–August) on a 0–3 scale (0 = none,
1 = mild, 2 = moderate and 3 = severe; maximum total
score = 15). Participants with a score ‡5 were included.
Participants with daily pulmonary inhaled glucocorticoids
during ‡3 months in the preceding year, or immunotherapy
in the preceding 3 yr were excluded. Other exclusion criteria
were sensitization (speciﬁc IgE ‡ 0.7 kU/l; Phadia) to pets
present in the family home, nasal abnormalities requiring sur-
gery and general contra-indications for immunotherapy (14).
The participants were allowed to be sensitized to birch pollen
and house dust mite. In the Netherlands, the birch pollen
season precedes the grass pollen season, whereas the peak of
the house dust mite season follows the grass pollen season.
Participants were included in two consecutive years. Both
cohorts entered the trial and started treatment after the grass
pollen season, in September–October and participated for
2 yr. Data from the overlapping year (i.e. the second pollen
season of the ﬁrst cohort and the ﬁrst pollen season of the
second cohort) were selected for the present analysis. Most
importantly, data from both treatment groups were pooled,
as there were no differences between treatment groups in the
primary and secondary outcome measures of the trial, includ-
ing symptom score and disease-speciﬁc quality of life (5).
Exposure
Daily pollen counts were obtained from the pollen monitor-
ing station in Leiden (Burkard pollen trap, Leiden University
Medical Centre, the Netherlands). These counts represent the
pollen exposure in the region where the participants were
recruited and evaluated. In the Netherlands, the grass pollen
season starts in May, with low pollen counts, and the highest
pollen counts are recorded in June.
Patient-reported outcomes
In general, the PROs were interview-administered in children
and self-administered in adolescents. A parent or research
assistant was allowed to assist, provided that they would not
inﬂuence the response of the participant. The study design is
presented in Fig. 1.
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Rhinoconjunctivitis-speciﬁc quality of life questionnaire
(RQLQ)
The disease-speciﬁc quality of life was assessed using the vali-
dated paediatric (6–11 yr; PRQLQ) (8) and adolescent (12–
17 yr; AdolRQLQ) (9) rhinoconjunctivitis quality of life
questionnaire. The PRQLQ consists of 23 items in ﬁve
domains: ‘nose symptoms’, ‘eye symptoms’, ‘practical prob-
lems’, ‘activities’ and ‘other symptoms’. The AdolRQLQ con-
sist of 25 items in six domains: ‘nose symptoms’, ‘eye
symptoms’, ‘practical problems’, ‘activities’, ‘emotional symp-
toms’ and ‘non-hay fever symptoms’. For the domain ‘activi-
ties’, the adolescents identiﬁed three activities from a
predeﬁned list that were performed on a regular basis and
that were impaired by their nose/eye symptoms. These activi-
ties were identiﬁed at the ﬁrst visit and remained speciﬁc for
that participant throughout the trial.
The participants were asked to recall their experiences dur-
ing the previous 7 days. Each item is scored on a 7-point
ordinal scale ranging from 0 (‘no impairment’) to 6 (‘maxi-
mum impairment’). The RQLQs were completed during two
house visits: one in a period with low exposure (May) and
the other in a period with high pollen counts (June). Only
complete questionnaires were analysed. The mean overall
score and the mean score for each domain separately in the
low and high pollen period were calculated (range 0–6).
COOP/WONCA-charts (CWC)
The CWC measure six core aspects of functional status:
‘physical ﬁtness’, ‘feelings’, ‘daily activities’, ‘social activities’,
‘change in health’ and ‘overall health’. Each domain is rated
on a 5-point ordinal scale ranging from one (‘no limitation at
all’) to ﬁve (‘severely limited’); for the domain ‘change in
health’ score one indicates ‘much better’ and score ﬁve ‘much
worse’. The recall period is 14 days (13). The questionnaire
was completed during the same visits as the RQLQ and only
complete questionnaires were analysed. The mean overall
score and the mean score for each domain separately in the
low and high pollen period were calculated (range 1–5).
Diary card (DC)
Participants scored ﬁve symptoms – sneezing, itching nose,
watery running nose, nasal blockage and itching eyes – on a
0–3 scale (0 = none, 1 = mild, 2 = moderate and
3 = severe) on diary cards during the period May 1–August
31. For the comparison with the RQLQ, the 7 days in the
diary card that corresponded with the recall period of the
RQLQ were analysed, provided that on at least 4 days all
ﬁve symptoms were recorded. For the comparison with the
CWC, the 14 days in the diary card that corresponded with
the recall period of the CWC were analysed, provided that
on at least 8 days all ﬁve symptoms were recorded. The mean
total symptom score (range 0–15), the mean total nose symp-
tom score (range 0–12) and the mean total eye symptom
score (range 0–3) during the low and high pollen period were
calculated. Also, the mean total symptom score for the whole
season (May–August) was calculated (range 0–15). For the
latter analysis, only pollen relevant days were analysed (i.e.
days with a pollen count that exceeded the median pollen
count of that season), provided that on at least 50% of the
days all ﬁve symptoms were recorded.
Global assessment of symptoms
After the grass pollen season, the participants evaluated their
complaints during the previous season (i.e. May–August in
the second year of the ﬁrst cohort and the ﬁrst year of the
second cohort) by scoring ﬁve symptoms – sneezing, itching
nose, watery running nose, nasal blockage and itching eyes
on a 0–3 scale (0 = none, 1 = mild, 2 = moderate and
3 = severe). The mean total score was calculated (range 0–
15).
Statistical analysis
Only participants with an analysable RQLQ, CWC and DC,
in both the RQLQ-week and CWC-weeks, were analysed.
Children (6–11 yr) and adolescents (12–17 yr) were analysed
separately, because the PRQLQ and AdolRQLQ contain dif-
ferent items and therefore cannot be combined.
Comparison of the scores between the low and high pollen
period was performed using the paired Wilcoxon test. The
limit of signiﬁcance in these comparisons was considered
p = 0.05 (two-sided).
The minimal important difference (MID) for the RQLQ is
0.5 (15). Changes larger than 1.0 and 1.5 are considered mod-
erate and large differences, respectively (15). The MID for
the CWC is unknown.
The correlation between the different PROs was analysed
using Spearman’s correlation. In view of the multitude of
GAS 
DC










Figure 1 Study design. CWC, COOP/WONCA-charts; DC, Diary Card; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire; GAS, Global
assessment of symptoms.
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correlations analysed, we set the level of signiﬁcance at
p = 0.01 (two-sided) in these analyses. A correlation coefﬁ-
cient (r) ‡0.7 is generally considered to represent a strong
correlation, a coefﬁcient between 0.5 and 0.7 a moderate cor-
relation, between 0.3 and 0.5 a weak correlation and below
0.3 as little if any correlation (16).
To identify the most important impairments as perceived
by the patients in both periods, the items and domains of the
HRQL questionnaires were ranked according to severity (i.e.
from highest to lowest mean score).
Determination of relevance
The overall RQLQ and CWC were considered relevant if the
following conditions were met:
1. The total score was responsive to exposure: the score in
the high pollen period was higher compared with the score in
the low pollen period and this difference was statistically sig-
niﬁcant and, in case, a minimal important difference (MID)
is known, also clinically relevant.
2. The total score correlated with the rhinoconjunctivitis
symptoms: the score in the high pollen period had at least a
statistically signiﬁcant moderate correlation with the DC total
score in the same period and the change in the HRQL total
score had at least a statistically signiﬁcant moderate correla-
tion with the change in DC total score (changes in outcomes
are represented by the symbol ‘D’ in text and tables).
The same conditions were used for the determination of
the relevance of the separate RQLQ and CWC-domains.
Only condition 1 was considered for the RQLQ items.
The retrospective GAS was considered a relevant represen-
tative of the actual complaints during the season if the corre-
lation with the mean total symptom score of the DC for the
whole season was at least strong.
Results
At the beginning of the grass pollen season, 55 children and
116 adolescents were participating in the study. Owing to
drop-out and incomplete diary cards and/or questionnaires,
18 children and 53 adolescents could not reliably be evalu-
ated and were excluded from the analyses. The data from
one child were not analysed because both house visits took
place in a high pollen period. In total, 36 children (mean age
[SD] 9.4 [1.3] yr; 25 boys/11 girls) and 63 adolescents (mean
age [SD] 14.0 [1.7] yr; 33 boys/30 girls) were analysed. In
both age groups, there were no signiﬁcant differences with
respect to age, gender and the retrospective symptom score at
the start of the trial between participants who were included
in the analyses compared with those who were excluded.
Relevance of the RQLQ and CWC
For all children and adolescents, the mean grass pollen count
in the evaluated RQLQ-week and CWC-weeks was higher in
the high pollen period. The total scores of all PROs (RQLQ,
CWC and related DCs) were signiﬁcantly higher in the high
pollen period in both age groups (Table 1 and E1).
The change in total scores (D) of the PRQLQ and Adol-
RQLQ reached the MID-limit. The total scores of the
RQLQs in the high pollen period showed a strong correlation
with the DC total scores and the changes in scores of both
RQLQs showed a moderate correlation with the changes in
DC total scores (Table 2, column ‘DC total’). Consequently,
the overall PRQLQ and AdolRQLQ are considered relevant.
The PRQLQ domain ‘other symptoms’ and the Adol-
RQLQ domains ‘non-hay fever symptoms’ and ‘emotional
symptoms’ did not reach the MID threshold, nor did they
fulﬁl our criteria for the correlations. Therefore, those
domains are not considered relevant. We found strong associ-
ations (r ‡ 0.70) between the DC and the RQLQ domains
covering nasal or eye symptoms. If RQLQ total scores are
calculated without the nose and eye symptom domains, the
changes in both adjusted total scores were signiﬁcant
(p £ 0.01). The change in the adjusted total score of the
PRQLQ was 0.7 and the difference in the adjusted Adol-
RQLQ total score just failed to reach the MID-limit. The
correlations with the DC total scores were also lower, but
still signiﬁcant (Children: low pollen r = 0.44/high pollen
r = 0.65/D r = 0.60. Adolescents: low pollen r = 0.67/high
pollen r = 0.68/D r = 0.57. All p-values £ 0.01).
As stated before, the CWC total scores were responsive to
exposure. This was also the case for the domain ‘overall
health’ in both age groups and the domain ‘change in health’
in children and ‘daily activities’ in adolescents (Table E1).
Analysis of the relationship between the CWC and DC
yielded mainly weak correlations (r < 0.50; Table E2, col-
umn ‘DC total’). Therefore, the overall CWC and its separate
domains cannot be considered relevant in both age groups,
although in children the CWC total score and the domain
‘overall health’ just failed to meet the conditions concerning
the correlation with symptoms.
We also investigated the correlation between the separate
DC domains ‘nose symptoms’ and ‘eye symptom’ and the
total and domain scores of both HRQLs (Table 2 and E2,
column ‘DC-nose’ and ‘DC-eye’). The results of these analy-
ses correspond with the results of the correlations between
the DC total score and the HRQLs.
All RQLQ items had a higher mean score in the high pol-
len period, except the item ‘headache’ in the adolescent
group. Changes in 4 of 23 PRQLQ items and 10 of 25 Adol-
RQLQ items were below the MID-limit of 0.5. In children, 7
items of various domains fulﬁlled the criterion of a moderate
change, whereas in adolescents only the item ‘red eyes’
reached this limit. The change in PRQLQ item ‘take
medications’ was the only large difference. For an item to be
considered relevant, the change in scores had to reach the
MID-limit and be statistically signiﬁcant. In children, 13 of
the 23 items met these criteria, and in adolescents 15 of 25.
Most important impairments
In both age groups and both pollen periods’ the RQLQ
domain ‘nose symptoms’ had the highest score followed by
the practical problems domain in children and the activity
domain in adolescents (Table 1).
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Looking at the RQLQ items, there were no major
differences between the low and high pollen period. The
PRQLQ and AdolRQLQ items with the highest mean
scores were the ﬁve nose and eye symptoms that were
also recorded in the DC, practical problems (like ‘rub eyes/
nose’ and ‘blow nose’) and activities. Notable is the
high score for ‘thirst’ in children, rank three in both peri-
ods.
In both age groups and in both pollen periods, the CWC-
domains ‘change in health’ and ‘overall health’ are the items
with the highest mean scores (Table E1).
Relevance of the GAS
The mean GAS in children and adolescents was 6.5 (range
1–12) and 6.8 (range 0–13), respectively. The mean DC total
Table 1 Paediatric and adolescent rhinoconjunctivitis quality of life questionnaire: Relevance and most important impairments
Low pollen High pollen D
(A) 6–11 yr
Pollen Median (range) Median (range)
3.0 (2.4 to 24.7) 93.7 (57.0 to 239.3)
DC Mean (range) Mean (range) Mean (range) p value
Total 2.5 (0 to 9.6) 4.3 (0 to 10.6) 1.8 ()6.0 to 10.4) #
RQLQ Mean (range) Rank Mean (range) Rank Mean (range) p value
Total 1.1 (0.3 to 2.8) 1.8 (0.1 to 5.4) 0.8 ()0.9 to 4.6) # R
Domain
Nose symptoms 1.9 (0.5 to 4.0) 1 2.8 (0.3 to 6.0) 1 0.9 ()1.8 to 4.3) # R
Practical problems 1.2 (0 to 3.8) 2 2.0 (0 to 5.8) 2 0.8 ()1.4 to 5.2) # R
Other symptoms 0.9 (0 to 2.2) 3 1.3 (0 to 4.0) 5 0.4 ()0.8 to 3.0) # –
Eye symptoms 0.8 (0 to 3.3) 4 1.9 (0 to 5.5) 3 1.0 ()1.3 to 5.0) # R
Activities 0.6 (0 to 3.3) 5 1.4 (0 to 6.0) 4 0.8 ()1.8 to 6.0) # R
Item
Sneezing* (N) 2.7 (0 to 5) 1 3.3 (1 to 6) 2 0.6 ()4 to 4) ns –
Rub nose/eyes (PR) 2.4 (0 to 6) 2 3.4 (0 to 6) 1 1.1 ()4 to 6) $ R
Thirst (O) 2.4 (0 to 6) 3 3.0 (0 to 6) 3 0.7 ()3 to 5) ns –
Itchy eyes* (E) 2.0 (0 to 6) 4 2.9 (0 to 6) 4 0.9 ()5 to 4) # R
Itchy nose* (N) 1.8 (0 to 5) 5 2.6 (0 to 6) 6 0.8 ()2 to 4) $ R
Blow nose (PR) 1.8 (0 to 6) 6 2.5 (0 to 6) 8 0.7 ()5 to 5) ns –
Stuffy/blocked nose* (N) 1.7 (0 to 5) 7 2.9 (0 to 6) 5 1.2 ()2 to 5) # R
Playing outdoors (A) 1.3 (0 to 6) 8 2.5 (0 to 6) 7 1.2 ()2 to 6) # R
Runny nose* (N) 1.2 (0 to 6) 9 2.4 (0 to 6) 9 1.2 ()3 to 5) # R
Take medications (PR) 0.9 (0 to 5) 10 2.4 (0 to 6) 10 1.5 ()3 to 6) # R
Headache (O) 0.9 (0 to 5) 11 1.0 (0 to 4) 17 0.1 ()2 to 4) ns –
Carry kleenex (PR) 0.8 (0 to 6) 12 1.5 (0 to 6) 12 0.8 ()3 to 6) $ R
Scratchy/itchy throat (O) 0.7 (0 to 6) 13 1.3 (0 to 6) 15 0.6 ()3 to 6) ns –
Watery eyes (E) 0.6 (0 to 5) 14 1.8 (0 to 6) 11 1.3 ()1 to 5) # R
Sore eyes (E) 0.5 (0 to 3) 15 1.2 (0 to 6) 16 0.7 ()2 to 6) $ R
Hard to get to sleep (A) 0.5 (0 to 2) 16 1.3 (0 to 6) 14 0.8 ()2 to 6) # R
Tired (O) 0.4 (0 to 2) 17 0.9 (0 to 5) 18 0.5 ()2 to 4) $ R
Do not feel well all over (O) 0.4 (0 to 2) 18 0.7 (0 to 6) 22 0.3 ()1 to 6) ns –
Hard to pay attention (A) 0.4 (0 to 2) 19 0.9 (0 to 6) 19 0.5 ()2 to 6) ns –
Irritable (O) 0.3 (0 to 3) 20 0.8 (0 to 5) 21 0.4 ()1 to 4) $ –
Wake up during night (A) 0.3 (0 to 3) 21 0.9 (0 to 6) 20 0.5 ()2 to 6) ns –
Swollen/puffy eyes (E) 0.3 (0 to 2) 22 1.5 (0 to 5) 13 1.2 ()1 to 5) # R
Feel embarrassed (PR) 0.1 (0 to 2) 23 0.3 (0 to 5) 23 0.1 ()1 to 5) ns –
N = 36; Low pollen, May; High pollen, June; D, Difference: High pollen minus Low pollen.
DC, Diary Card (scale 0–15). RQLQ, Paediatric rhinoconjunctivitis quality of life questionnaire (scale 0–6, a higher score indicates a lower
quality of life).
*Symptoms also recorded in the diary card.
Corresponding domains: A = Activities; E = Eye symptoms; N = Nose symptoms; O = Other symptoms; PR = Practical problems.
#p £ 0.01; $p £ 0.05.
R, relevant; for the total and domain scores, the results from the correlation analyses (see Table 2) were also incorporated.
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symptom score in children and adolescents was 3.7 (range
0.6–8.2) and 3.8 (range 0.3–9.8), respectively. The correlation
between the GAS and the DC total symptom score of the
whole season was 0.42 both in children and adolescents. The
correlation between the GAS and other in season PRO total
scores was lower, except for the RQLQ total score in the low
Table 1 (Continued)
Low pollen High pollen D
(B) 12–17 yr
Pollen Median (range) Median (range)
3.0 (2.4 to 24.7) 87.0 (46.3 to 239.3)
DC Mean (range) Mean (range) Mean (range) p value
Total 3.2 (0 to 10.0) 4.7 (0 to 12.0) 1.5 ()3.6 to 7.9) #
RQLQ Mean (range) Rank Mean (range) Rank Mean (range) p value R
Total 1.3 (0 to 4.7) 1.8 (0 to 4.5) 0.5 ()1.5 to 3.2) # R
Domain
Nose symptoms 2.2 (0 to 6.0) 1 2.8 (0 to 6.0) 1 0.7 ()2.5 to 4.8) # R
Activities 1.9 (0 to 5.0) 2 2.4 (0 to 6.0) 2 0.5 ()2.0 to 4.7) # R
Eye symptoms 1.4 (0 to 5.5) 3 2.3 (0 to 6.0) 3 0.9 ()2.8 to 5.8) # R
Practical problems 1.3 (0 to 5.4) 4 2.0 (0 to 5.4) 4 0.7 ()2.0 to 3.6) # R
Non-hay fever symptoms 0.8 (0 to 5.0) 5 1.1 (0 to 5.0) 5 0.3 ()3.0 to 2.4) # –
Emotional symptoms 0.4 (0 to 3.5) 6 0.6 (0 to 4.3) 6 0.2 ()1.3 to 3.0) $ –
Item
Rub nose/eyes (PR) 2.7 (0 to 6) 1 3.4 (0 to 6) 1 0.7 ()3 to 5) # R
Sneezing* (N) 2.5 (0 to 6) 2 3.1 (0 to 6) 2 0.5 ()2 to 4) # R
Itchy eyes* (E) 2.2 (0 to 6) 3 3.0 (0 to 6) 3 0.8 ()4 to 6) # R
Stuffy/blocked nose* (N) 2.1 (0 to 6) 4 2.9 (0 to 6) 4 0.8 ()3 to 6) $ R
Itchy nose* (N) 2.1 (0 to 6) 5 2.8 (0 to 6) 5 0.7 ()3 to 6) # R
Activity 2 (A) 2.0 (0 to 6) 6 2.5 (0 to 6) 8 0.5 ()3 to 6) ns –
Runny nose* (N) 1.9 (0 to 6) 7 2.5 (0 to 6) 6 0.6 ()5 to 6) $ R
Activity 1 (A) 1.9 (0 to 6) 8 2.3 (0 to 6) 12 0.4 ()3 to 5) $ –
Activity 3 (A) 1.7 (0 to 6) 9 2.3 (0 to 6) 11 0.6 ()3 to 6) # R
Blow nose (PR) 1.7 (0 to 6) 10 2.5 (0 to 6) 7 0.8 ()4 to 5) # R
Watery eyes (E) 1.6 (0 to 6) 11 2.4 (0 to 6) 9 0.8 ()4 to 6) # R
Carry kleenex (PR) 1.4 (0 to 6) 12 2.1 (0 to 6) 13 0.7 ()4 to 6) # R
Tired/worn out (NH) 1.2 (0 to 6) 13 1.3 (0 to 5) 17 0.1 ()4 to 4) ns –
Red eyes (E) 1.2 (0 to 5) 14 2.4 (0 to 6) 10 1.2 ()5 to 6) # R
Thirst (NH) 1.1 (0 to 6) 15 1.6 (0 to 6) 14 0.5 ()2 to 3) # R
Headache (NH) 0.8 (0 to 5) 16 0.8 (0 to 5) 22 )0.1 ()3 to 3) ns –
Irritable (F) 0.7 (0 to 5) 17 1.0 (0 to 6) 18 0.3 ()4 to 5) ns –
Swollen eyes (E) 0.7 (0 to 5) 18 1.4 (0 to 6) 15 0.8 ()5 to 6) # R
Lack of good night’s sleep (PR) 0.5 (0 to 6) 19 1.4 (0 to 6) 16 0.9 ()4 to 5) # R
Generally do not feel well (NH) 0.5 (0 to 5) 20 0.9 (0 to 5) 20 0.4 ()3 to 5) $ –
(school) work (PR) 0.5 (0 to 6) 21 0.8 (0 to 5) 21 0.3 ()6 to 5) $ –
Can not concentrate (NH) 0.4 (0 to 6) 22 1.0 (0 to 5) 19 0.5 ()6 to 4) # R
Frustrated (F) 0.4 (0 to 5) 23 0.4 (0 to 5) 24 0.0 ()3 to 2) ns –
Restless (F) 0.3 (0 to 2) 24 0.7 (0 to 5) 23 0.4 ()2 to 5) $ –
Upset/embarrassed§ (F) 0.2 (0 to 2) 25 0.3 (0 to 6) 25 0.1 ()2 to 6) ns –
N = 63; Low pollen, May; High pollen, June; D, Difference: High pollen minus Low pollen.
DC, Diary card (scale 0–15); RQLQ, Adolescent rhinoconjunctivitis quality of life questionnaire (scale 0–6, a higher score indicates a lower
quality of life).
*Symptoms also recorded in the diary card.
corresponding domains: A = Activities; E = Eye symptoms; F = Emotional symptoms; N = Nose symptoms; NH = Non-hay fever symp-
toms; PR = Practical problems.
Complete description: unable to do (school) work as well as usual.
§Complete description: upset/embarrassed by other’s response to your hay fever symptoms.
#p £ 0.01; p £ 0.05.
R, relevant; for the total and domain scores the results from the correlation analyses (see Table 2) were also incorporated.
Relevance of patient-reported outcomes Ro¨der et al.
44 Pediatric Allergy and Immunology 24 (2013) 39–48 ª 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
and high pollen period in adolescents (r = 0.49 and
r = 0.53, respectively; Table 3).
Discussion
Patient-reported outcomes, which are subjective measures,
are the only outcomes available to evaluate the effects of
medication or other interventions in patients with allergic
rhinoconjunctivitis. The acknowledgement that allergic rhi-
noconjunctivitis can signiﬁcantly inﬂuence the patient’s
quality of life because of its impact on daily activities,
school and work performance (1) led to the development
of disease-speciﬁc questionnaires. Rhinoconjunctivitis
quality of life questionnaires (RQLQs) designed for adults
(17), adolescents (9) and children (8) are now available.
The items of the RQLQs reﬂect the most important
impairments as reported by patients in each speciﬁc age
group. Nowadays, assessment of disease-speciﬁc quality of
life is an essential part of randomized controlled trials
(RCTs) in allergic rhinoconjunctivitis. On the other hand,
generic quality of life instruments are not commonly used
in these RCTs. Generic HRQL measures are less sensitive
Table 2 Correlation between diary card and paediatric and adolescent rhinoconjunctivitis quality of life questionnaire
DC Total DC Nose DC Eye
RQLQ 6–11 yr Total Low pollen 0.64 0.62 –
High pollen 0.74 0.72 0.67
D 0.64 0.60 0.52
Nose Low pollen 0.64 0.67 –
High pollen 0.74 0.75 0.57
D 0.68 0.67 0.43
Eye Low pollen 0.51 – 0.75
High pollen 0.64 0.57 0.74
D 0.60 0.49 0.68
Activities Low pollen – – –
High pollen 0.58 0.58 0.50
D 0.61 0.59 0.50
Practical Low pollen – – –
High pollen 0.67 0.65 0.62
D 0.67 0.60 0.56
Other Low pollen – – –
High pollen 0.52 0.51 0.49
D – – –
12–17 yr Total Low pollen 0.77 0.75 0.51
High pollen 0.77 0.74 0.71
D 0.68 0.68 0.54
Nose Low pollen 0.80 0.82 0.40
High pollen 0.78 0.77 0.61
D 0.67 0.71 0.44
Eye Low pollen 0.63 0.52 0.76
High pollen 0.70 0.64 0.79
D 0.69 0.62 0.70
Activities Low pollen 0.61 0.59 0.45
High pollen 0.56 0.52 0.56
D 0.55 0.52 0.53
Practical Low pollen 0.68 0.69 0.34
High pollen 0.69 0.68 0.55
D 0.55 0.59 0.33
Emotional Low pollen 0.40 0.40 –
High pollen 0.49 0.48 0.37
D – – –
Non-hay fever Low pollen 0.41 0.39 –
High pollen 0.61 0.58 0.58
D 0.35 0.40 –
6–11 yr n = 36; 12–17 yr n = 63. In the rows labelled ‘low pollen’ and ‘high pollen’ the correlations are shown for the scores in May and
June, respectively. In the rows labelled ‘D’, the correlations are shown for the changes (high pollen minus low pollen) of both scores.
Spearman’s correlation; only significant correlations (p £ 0.01) are shown.
DC, Diary card; RQLQ, Rhinoconjunctivitis quality of life questionnaire.
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to capture small but important changes that may occur in
the course of a disease, for instance before and after treat-
ment. On the other hand, they can be used to compare
the impairments caused by different diseases and some gen-
eric HRQL measures are used in cost-effectiveness analyses.
In contrast to the disease-speciﬁc RQLQ, no widely
accepted generic list is available for children. We wished to
explore the properties of the CWC being a simple and
short instrument. The CWC were developed as a screening
instrument in general practice. If the responses indicate a
decrease in health status, a longer and more sophisticated
instrument can be used to get more precise information
(11–13). As the CWC are validated for adults only, we did
not incorporate the CWC in our analysis of the efﬁcacy of
sublingual immunotherapy in children and adolescents.
However, the immunotherapy trial provided us with the
opportunity to test the responsiveness to pollen exposure
and to correlate the outcome of the CWC with rhinocon-
junctivitis symptoms. In case of responsiveness and moder-
ate correlation, a formal validation would be the next step.
In this study, we looked at the relevance of the RQLQ
and CWC in an immunotherapy trial in young patients with
hay fever. First, we evaluated the outcome measures in terms
of responsiveness to pollen exposure. In our opinion, symp-
toms or problems not responding to increased pollen expo-
sure are irrelevant in the context of well-established pollen
allergy. All PROs appeared to be responsive to higher pollen
exposure. The clinical signiﬁcance of the observed changes of
the CWC cannot be estimated as information about the MID
of this instrument is not available. The RQLQs showed het-
erogeneity in responsiveness. Although changes in total
scores and most domains reached the limit of 0.5, one-sixth
of differences in the PRQLQ items and almost one-third of
the changes in AdolRQLQ items remained under the level of
clinical signiﬁcance.
Secondly, we expected a relationship with the classical
symptoms of rhinoconjunctivitis as recorded with diary cards.
It does not make sense to assess symptoms or problems that
are apparently not related to the features of nasal disease.
The PRQLQ and the AdolRQLQ both performed better than
the CWC, with respect to the total scores as well as to the
separate domains. The CWC showed predominantly weak
correlations or no signiﬁcant correlations with daily symp-
toms at all. The analysis of the different domains of both
RQLQs however revealed again domains that did not fulﬁl
the correlation criteria.
In a clinical trial, participants should not be burdened
with questions that address the same aspects of a disease. In
our study, we found strong correlations between the nasal
and eye domains of the DC and the RQLQ. This is not
unexpected, as answers to questions about severity, frequency
and impact of symptoms – although differently phrased –
will be inter-related, in particular if they are put to patients
in the same time frame. When the nose and eye domains
were removed from the RQLQs, the PRQLQ was still
responsive to exposure, but the AdolRQLQ just failed to
reach the MID-limit. As anticipated, the correlations with
the DC were somewhat lower, but still highly signiﬁcant. It
would be interesting to investigate whether an adjusted ver-
sion of the RQLQ without nose and eye symptoms might be
a relevant addition to the DC in clinical trials. Another
option to minimize overlap is replacing the diary card with
the RQLQ and using the RQLQ as a primary outcome. In a
GA2LEN paper on the conduct of immunotherapy trials, it
was stated that HRQL measures may soon become primary
outcomes (18). In contrast, the WAO stated on the same
issue that this is not possible, partly because there is no
accepted way of correcting the use of rescue medication (3).
However, this is also true for the classical symptom scores as
still no widely used standardized method of combining symp-
tom severity and medication use is available. Recently, three
interesting articles were published addressing these issues.
Ha¨fner et al. as well as Grouin et al. (19, 20) validated a
new combined symptom-medication score. Franzke et al.
(21) on the other hand, focussed on the patient’s needs and
beneﬁts and developed a new instrument for the assessment
of patient-deﬁned beneﬁt that can be used for the evaluation
of allergic rhinitis treatments. Besides addressing the same
issues in different questionnaires, asking questions that are
not relevant should be avoided. In both age groups, 40% of
the RQLQ items were not relevant. Removing these items
from the questionnaires results in shorter lists with mere rele-
vant questions, which will enhance compliance. For adults
such a shortened version of the RQLQ, the mini-RQLQ, is
already available (22). Furthermore, both PRQLQ and Adol-
Table 3 Correlation between the global assessment of symptoms,
diary card, rhinoconjunctivitis quality of life questionnaire and
COOP/WONCA-charts
GAS
6–11 yr DC Whole season 0.42
Low pollen RQLQ-week –
CWC-weeks –
high pollen RQLQ-week –
CWC-weeks –
RQLQ low pollen –
high pollen –
CWC low pollen –
high pollen –
12–17 yr DC whole season 0.42
low pollen RQLQ-week 0.36
CWC-weeks 0.37
high pollen RQLQ-week 0.41
CWC-weeks 0.37
RQLQ low pollen 0.49
high pollen 0.53
CWC low pollen –
high pollen 0.36
6–11 yr n = 36; 12–17 yr n = 61. In the rows labelled ‘whole sea-
son’, ‘low pollen’ and ‘high pollen’, the correlations are shown for
the total scores in May–August, May and June, respectively. Spear-
man’s correlation; only significant correlations (p £ 0.01) are shown.
DC, Diary card; CWC, COOP/WONCA-charts; GAS, global assess-
ment of symptoms; RQLQ, rhinoconjunctivitis quality of life ques-
tionnaire.
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RQLQ are developed by and validated in patients with pol-
len-induced allergic rhinitis. It has been suggested that the
lists might be missing some important items for patients with
persistent rhinitis caused by exposure to indoor allergens,
such as snoring and mouth breathing (23). Therefore, it
would be interesting to assess the relevance of the complete
and/or shortened questionnaires in for instance house dust
mite allergic patients.
Clinically relevant differences in symptom or HRQL
scores can only be detected if patients with sufﬁcient symp-
toms are included in a study. To select such patients a
baseline period (i.e. observation during the season before
randomization) could be used. In grass pollen immunother-
apy trials, a baseline season is not mandatory, because of
the variability in exposure between seasons (23). In some
trials, participants are selected only on the basis of having
experienced rhinoconjunctivitis symptoms during the previ-
ous year(s) (24, 25). Others also assess the severity of
symptoms by using a retrospective assessment of symptoms
during the previous season to select patients with sufﬁcient
symptoms (26). In our study, the GAS overrated the sever-
ity of the actual symptoms during the season and the cor-
relation between the GAS and the DC was statistically
signiﬁcant, but not strong. This result resembles the out-
come of a study performed in adults where the retrospec-
tive assessment also overrated the severity of and only had
a fair to moderate agreement with the in season assessment
(27). The phrasing of the GAS is not the same in all trials.
For instance, Wahn et al. (26) asked the patients to assess
the worst symptoms during the season and not evaluate
the symptoms during the whole of the season. Further
research is needed to determine whether rephrasing the
questions might improve the correlation of this retrospec-
tive assessment with the in season symptom scores. Our
ﬁndings on the GAS have implications going beyond
RCTs. Physicians often see patients after the season and
rely on the severity of symptoms and the effect of treat-
ment as perceived retrospectively by patients. Our results
point at the imprecision of such statements.
Another result that can be helpful for physicians when
treating children and adolescents with hay fever is the analy-
sis of the separate items of the RQLQs, as this analysis may
give valuable information on the problems these patients
experience. In general, children and adolescents are bothered
by the same issues. In daily practice, evaluation of symp-
toms, practical problems (like rubbing nose/eyes) and impair-
ment in activities will give a good impression of the impact
of the disease. It appears that children also perceive thirst as
an important issue, a complaint that is not spontaneously
brought to the physician’s attention. In children, special
attention should also be paid to medication use. When pollen
exposure rises, taking their medication becomes much more
bothersome to children, which might lead to non-compliance
and consequently more symptoms. As the pollen season pro-
gresses, both adolescents and children experience a substan-
tial impact from eye symptoms. Emotional problems, such as
embarrassment and frustration, are considered least impor-
tant in both age groups.
This study has a few limitations. First, the study is
mainly exploratory and derived from a dataset from a
RCT. However, as the instruments are designed to be used
in clinical trials, this study population is appropriately
composed to evaluate the properties of the instruments.
Secondly, the numbers of participants are small, however
they appeared to be sufﬁcient for the analyses we made.
Larger study groups and an extension to adults may how-
ever strengthen our ﬁndings. Thirdly, the relevance of the
HRQL questionnaires was based on assumptions about the
meaning of the correlations. Such assumptions are helpful
in deciding what is important, but they have to be used
with caution.
In conclusion, we demonstrated that the paediatric and
adolescent RQLQ are relevant as they both are responsive to
exposure and correlate well with rhinoconjunctivitis symp-
toms in pollen seasons. However, both RQLQs contain a
substantial number of irrelevant items and therefore both
questionnaires could be shortened. Furthermore, our data
showed that the CWC are not relevant in the monitoring of
children and adolescents with allergic rhinoconjunctivitis. In
this study, the retrospective GAS was not a relevant repre-
sentative of the actual symptoms during the previous season.
Because the GAS is used as an evaluation tool in research as
well as in daily practice, further research is needed to deter-
mine whether for instance rephrasing the questions, for
example, focusing on days with severe symptoms, might
improve this retrospective assessment.
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Table E1 COOP/WONCA-charts: Relevance and most important impairments
Low pollen High pollen D
(A) 6–11 yr
Pollen Median (range) Median (range)
2.6 (1.9 to 16.6) 102.6 (61.1 to 175.4)
DC Mean (range) Mean (range) Mean (range) p value
Total 2.4 (0 to 8.5) 4.5 (0.1 to 12.5) 2.1 ()3.2 to 12.3) #
CWC Mean (range) Rank Mean (range) Rank Mean (range) p value R
Total 1.6 (1.0 to 2.7) 1.8 (1.2 to 4.2) 0.2 ()0.8 to 2.3) $ –
Domain
Change in health 2.3 (1 to 4) 1 2.8 (1 to 5) 1 0.6 ()1 to 4) # –
Overall health 1.8 (1 to 3) 2 2.3 (1 to 5) 2 0.5 ()2 to 4) $ –
Feelings 1.6 (1 to 5) 3 1.6 (1 to 5) 3 0.0 ()3 to 4) ns –
Physical fitness 1.5 (1 to 3) 4 1.5 (1 to 4) 4 0.0 ()1 to 1) ns –
Daily activities 1.3 (1 to 3) 5 1.4 (1 to 4) 5 0.2 ()2 to 3) ns –
Social activities 1.2 (1 to 4) 6 1.1 (1 to 3) 6 )0.1 ()2 to 1) ns –
(B) 12–17 yr
Pollen Median (range) Median (range)
2.6 (1.9 to 16.6) 99.7 (51.6 to 79.6)
DC Mean (range) Mean (range) Mean (range) p value
3.2 (0 to 8.4) 4.8 (0 to 10.3) 1.6 ()2.4 to 7.0) #
CWC Mean (range) Rank Mean (range) Rank Mean (range) p value R
Total 1.8 (1.0 to 3.7) 1.9 (1.2 to 3.5) 0.2 ()1.2 to 1.8) $ –
Domain
Change in health 2.7 (1 to 4) 1 2.8 (1 to 5) 1 0.1 ()3 to 3) ns –
Overall health 2.3 (1 to 5) 2 2.6 (1 to 5) 2 0.3 ()2 to 3) $ –
Feelings 1.8 (1 to 5) 3 1.7 (1 to 4) 4 )0.1 ()3 to 2) ns –
Daily activities 1.5 (1 to 4) 4 1.9 (1 to 4) 3 0.4 ()2 to 3) # –
Physical fitness 1.4 (1 to 3) 5 1.5 (1 to 3) 5 0.1 ()1 to 2) ns –
Social activities 1.1 (1 to 4) 6 1.2 (1 to 4) 6 0.1 ()2 to 3) ns –
6–11 yr n = 36; 12–17 yr n = 63.
Low pollen, May; High pollen, June; D, Difference: High pollen minus Low pollen.
CWC, COOP/WONCA-charts (scale 1–5, a higher score indicates a lower quality of life); DC, Diary card (scale 0–15).
#p £ 0.01; $p £ 0.05.
R, relevant; for the total and domain scores the results from the correlation analyses (see Table E2) were also incorporated.
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Table E2 Correlation between diary card and COOP/WONCA-
charts
DC Total DC Nose DC Eye
CWC 6–11 yr Total Low pollen – – –
High pollen 0.47 0.47 –
D 0.5 0.54 –
Physical
fitness
Low pollen – – –
High pollen – – 0.48
D 0.56 0.56 0.54
Feelings Low pollen – – –
High pollen – – –
D – – –
Daily
activities
Low pollen – – –
High pollen – – –
D – – –
Social
activities
Low pollen )0.43 )0.45 –
High pollen – – –
D – – –
Change in
health
Low pollen – – –
high pollen – – –
D – – –
Overall
health
low pollen – – –
high pollen 0.49 0.47 –
D 0.52 0.54 –
12–17 yr Total low pollen 0.35 0.35 –
high pollen 0.38 0.4 –
D – – –
Physical
fitness
low pollen – – –
high pollen – – –
D – – –
Feelings low pollen – – –
high pollen 0.31 0.29 0.32
D – – –
Daily
activities
low pollen – – –
high pollen 0.38 0.39 0.33
D 0.35 0.35 –
Social
activities
low pollen – – –
high pollen 0.35 0.34 –
D – – –
Change in
health
low pollen – – –
high pollen – – –
D – – –
Overall
health
low pollen 0.39 0.39 –
high pollen – – –
D 0.47 0.43 0.48
6–11 yr n = 36; 12–17 yr n = 63. In the rows labelled ‘low pollen’
and ‘high pollen’, the correlations are shown for the scores in May
and June, respectively. In the rows labelled ‘D’, the correlations are
shown for the changes (high pollen minus low pollen) of both
scores. Spearman’s correlation; only significant correlations
(p £ 0.01) are shown.
DC, Diary card; CWC, COOP/WONCA-charts.
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